Mantzaris G J, Karagiannis J A, Priddle J D, Jewell D P
Gastroenterology Unit, Radcliffe Infirmary, Oxford.
Gut. 1990 Jun;31(6):668-73. doi: 10.1136/gut.31.6.668.
The human intestinal adenovirus serotype 12 (Ad12) may be implicated in the pathogenesis of coeliac disease by virtue of immunological cross reactivity between epitopes shared by its early region E1b protein and A-gliadin. In the present study a synthetic dodecapeptide from the corresponding viral epitope (Ad12E1b, residues 384-395) was tested for its effect on peripheral blood mononuclear cells from 22 treated and eight untreated patients with coeliac disease, 22 healthy subjects, 11 patients with ulcerative colitis, and 11 patients with Crohn's disease by an indirect leucocyte migration inhibition assay. In addition, the effect of both the viral and the gliadin synthetic peptides was studied by proliferation and migration assays simultaneously performed in an unselected subgroup of 12 treated coeliac patients and 12 healthy subjects of the study. Coeliac patients with untreated disease showed no response to the viral peptide compared with treated patients (p greater than 0.1). Treated coeliac patients showed a significantly different response from healthy control subjects and control patients with disease (p less than 0.001) which was dependent on the concentration of the viral peptide. In the subgroup of the treated coeliac patients (n = 12) there was a significant correlation between the responses in the migration and the proliferation assay using either the viral (p less than 0.02) or the gliadin (p less than 0.005) peptide at the highest concentration (33.3 micrograms/ml). Furthermore, the responses obtained using viral peptide correlated significantly with the responses obtained with gliadin peptide in both the migration (p less than 0.001) and the proliferation (p less than 0.001) assays. These results show that in coeliac patients there is pronounced cross reactivity at the level of T cell recognition between synthetic peptides derived from the Ad12 and A-gliadin. This antigenic cross reactivity may be involved in the pathogenesis of coeliac disease.
人类肠道腺病毒12型(Ad12)可能因其早期区域E1b蛋白与A-麦醇溶蛋白共有的表位之间的免疫交叉反应而与乳糜泻的发病机制有关。在本研究中,通过间接白细胞迁移抑制试验,检测了来自相应病毒表位(Ad12E1b,第384 - 395位氨基酸残基)的合成十二肽对22例接受治疗和8例未接受治疗的乳糜泻患者、22名健康受试者、11例溃疡性结肠炎患者和11例克罗恩病患者外周血单个核细胞的影响。此外,在该研究中未经过挑选的12例接受治疗的乳糜泻患者和12名健康受试者亚组中,同时通过增殖和迁移试验研究了病毒和麦醇溶蛋白合成肽的作用。与接受治疗的患者相比,未接受治疗的乳糜泻患者对病毒肽无反应(p大于0.1)。接受治疗的乳糜泻患者与健康对照受试者和患病对照患者的反应有显著差异(p小于0.001),这取决于病毒肽的浓度。在接受治疗的乳糜泻患者亚组(n = 12)中,使用最高浓度(33.3微克/毫升)的病毒肽(p小于0.02)或麦醇溶蛋白肽(p小于0.005)进行迁移试验和增殖试验的反应之间存在显著相关性。此外,在迁移试验(p小于0.001)和增殖试验(p小于0.001)中,使用病毒肽获得的反应与使用麦醇溶蛋白肽获得的反应显著相关。这些结果表明,在乳糜泻患者中,源自Ad12和A-麦醇溶蛋白的合成肽在T细胞识别水平上存在明显的交叉反应。这种抗原交叉反应可能参与了乳糜泻的发病机制。